Keywords
How to Cite
Abstract
The review article summarizes the date of literature and our own research on the creation of more effective and safe domestic combined drugs with a pronounced anti-inflammatory and analgesic effects. Untimely treatment of inflammatory processes often leads to long-term disability and even disability, so today there is an active search for new effective and safe domestic combination drugs with pronounced anti-inflammatory and analgesic effects. The constant search for innovative drugs causes a significant number of diseases, pathological conditions for which treatment with existing drugs is not effective or causes addiction and a large number of side effects. Because of, inflammatory processes can be accompanied by severe pain, spasms, increased convulsive activity of the brain, other disorders of the body, so non-narcotic analgesics and nonsteroidal anti-inflammatory drugs are combined with other drugs that can cause complementary effects or potentiate each other's effects. Caffeine is a useful adjuvant of nonsteroidal anti-inflammatory drugs of various chemical structures in terms of anti-inflammatory and analgesic effects. The review article presents a literature review of the current state of treatment of inflammation and pain, conducting research to expand the therapeutic capabilities of known pharmaceuticals, the creation of pharmaceutical compositions of nonsteroidal anti-inflammatory drugs with caffeine.
References
Kyrychok, L. T., Trutaiev, I. V., & Fedorin, H. F. (2001). Kombinovani fitopreparaty – nove perspektyvne dzherelo farmakoterapii [Combined phytopreparations are new promising sources of pharmacotherapy]. Farmakolo-hiia 2001 – krok u maibutnie: materialy II Natsionalnoho zizdu farmakolohiv Ukrainy, Dnipropetrovsk [Pharmacology 2001 ‒ a step into the future: materials of the 1st National Congress of Pharmacologists of Ukraine, Dnipropetrovsk].
Lourens, D. R., & Bennyt, P. N. (1991). Vospalenye y nesteroydnye protyvovospalytelnye sredstva [Inflammatory and nonsteroidal anti-inflammatory drugs]. Klynycheskaia farmakolohyia [Clinical Pharmacology]. M., Medytsyna.
Ivanova, V.V., Govorova, L.V., Erbasskaya, A.V., & Alekseeva, L.A. (2012). Features of the response to in-flammatory process in children with high and low intensity of free radical oxidations in lymphocytes during the acute period of the disease in various ethnic groups. Journal Infectology, 4(3), 46‒52. https://doi.org/10.22625/2072-6732-2012-4-3-46-52
Brenneis, C., Coste, O., Altenrath, K., et al. (2011). Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem. 286(3), 2331-2342.
Crofford, L. J., Lipsky, P. E., Brooks, P., Abramson, S. B., Simon, L. S., & van de Putte, L. B. (2000). Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis and rheumatism, 43(1), 4–13. https://doi.org/10.1002/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V
Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala, N., Emberson, J., Merhi, A., Abramson, S., Arber, N., … & Baigent, C. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (London, England), 382(9894), 769–779. https://doi.org/10.1016/S0140-6736(13)60900-9
Das, S., Haldar, P. K., Pramanik, G., Panda, S. P., & Bera, S. (2011). Evaluation of analgesic and anti-inflammatory activity of diospyros cordifolia extract. African journal of traditional, complementary, and alternative medicines : AJTCAM, 8(1), 11–14.
Morrison, A., Ramey, D. R., van Adelsberg, J., & Watson, D. J. (2007). Systematic review of trials of the ef-fect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Current medical research and opinion, 23(10), 2395–2404. https://doi.org/10.1185/030079907X219553
Páramo, J. A., Beloqui, O., & Orbe, J. (2006). Ciclooxigenasa 2: 'una nueva diana terapéutica en la aterosclero-sis? [Cyclooxygenase-2: a new therapeutic target in atherosclerosis?]. Medicina clinica, 126(20), 782–786. https://doi.org/10.1157/13089104 [In Spanish].
Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arteriosclerosis, thrombosis, and vascular biology, 31(5), 986–1000. https://doi.org/10.1161/ATVBAHA.110.207449
Vu, D., Murty, M., & McMorran, M. (2002). Selective COX-2 inhibitors: suspected cardiovascu-lar/cerebrovascular adverse reaction. Canad. Adverse Reaction Newsletter, 12, 1‒4.
Nasonov, E. L., Yakhno, N. N., Karateev, A. E., et al. (2016). General principles of the treatment of musculo-skeletal pain: interdisciplinary consensus. Scientific and practical rheumatology, 54(3), 247‒265.
Laufer, S., Gay, S., & Brune, K. (2003). Inflammation and Rheumatic Diseases: The molecular basis of novel therapies. New York: Georg Thieme Verlag.
Visha, M. G. (2013). Selective Cox-2 inhibitor. Int. J. Pharm. Sci Interv., 3(2), 28‒33.
Schjerning Olsen, A. M., Gislason, G. H., McGettigan, P., Fosbøl, E., Sørensen, R., Hansen, M. L., … & Lamberts, M. (2015). Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA, 313(8), 805–814. https://doi.org/10.1001/jama.2015.0809
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., … & Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England journal of medicine, 352(11), 1092–1102. https://doi.org/ 10.1056/NEJMoa050493
Fanelli, A., Ghisi, D., Aprile, P. L., & Lapi, F. (2017). Cardiovascular and cerebrovascular risk with nonsteroi-dal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Therapeutic advances in drug safety, 8(6), 173–182. https://doi.org/10.1177/2042098617690485
Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala, N., Emberson, J., Merhi, A., Abramson, S., Arber, N., … & Baigent, C. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (London, England), 382(9894), 769–779. https://doi.org/10.1016/S0140-6736(13)60900-9
FitzGerald, G. A., & Patrono, C. (2001). The coxibs, selective inhibitors of cyclooxygenase-2. The New Eng-land journal of medicine, 345(6), 433–442. https://doi.org/10.1056/NEJM200108093450607
Brune, K., & Patrignani, P. (2015). New insights into the use of currently available non-steroidal anti-inflammatory drugs. Journal of pain research, 8, 105–118. https://doi.org/10.2147/JPR.S75160
Walter, M. F., Jacob, R. F., Day, C. A., Dahlborg, R., Weng, Y., & Mason, R. P. (2004). Sulfone COX-2 in-hibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis, 177(2), 235–243. https://doi.org/10.1016/j.atherosclerosis.2004.10.001
Solomon, S. D., McMurray, J. J., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., … & Adenoma Prevention with Celecoxib (APC) Study Investigators (2005). Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. The New England journal of medicine, 352(11), 1071–1080. https://doi.org/10.1056/NEJMoa050405
Simon, L. S. (2000). Are the biologic and clinical effects of the COX-2-specific inhibitors an advance compared with the effects of traditional NSAIDs? Current opinion in rheumatology, 12(3), 163–170. https://doi.org/10.1097/ 00002281-200005000-00001
Smith, W. L., & Langenbach, R. (2001). Why there are two cyclooxygenase isozymes. The Journal of clinical investigation, 107(12), 1491–1495. https://doi.org/10.1172/JCI13271
Wallace, J. L. (1999). Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs). The American journal of medicine, 107(6A), 11S–17S. https://doi.org/10.1016/s0002-9343(99)00363-0
Wallace, J. L., Bak, A., McKnight, W., Asfaha, S., Sharkey, K. A., & MacNaughton, W. K. (1998). Cycloox-ygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroen-terology, 115(1), 101–109. https://doi.org/10.1016/s0016-5085(98)70370-1
Dey, I., Lejeune, M., & Chadee, K. (2006). Prostaglandin E2 receptor distribution and function in the gastroin-testinal tract. British journal of pharmacology, 149(6), 611–623. https://doi.org/10.1038/sj.bjp.0706923
Van Hecken, A., Schwartz, J. I., Depré, M., De Lepeleire, I., Dallob, A., Tanaka, W., … & De Schepper, P. J. (2000). Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. Journal of clinical pharmacology, 40(10), 1109–1120.
Lanas, A., García-Rodríguez, L. A., Arroyo, M. T., Gomollón, F., Feu, F., González-Pérez, A., … & Aso-ciación Española de Gastroenterología (2006). Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut, 55(12), 1731–1738. https://doi.org/10.1136/gut.2005.080754
Barracchini, A., Franceschini, N., Amicosante, G., et al. (1998). Biochemistry: Can Non-steroidal Anti-inflammatory Drugs Act as Metalloproteinase Modulators? An In-vitro Study of Inhibition of Collagenase Activity. J. Pharm. Pharmacol., 50(12), 1417‒1423.
Holgate, S. T., Peters-Golden, M., Panettieri, R. A., & Henderson, W. R., Jr (2003). Roles of cysteinyl leuko-trienes in airway inflammation, smooth muscle function, and remodeling. The Journal of allergy and clinical immu-nology, 111(1 Suppl), S18–S36. https://doi.org/10.1067/mai.2003.25
Burnett, B. P., & Levy, R. M. (2012). 5-Lipoxygenase metabolic contributions to NSAID-induced organ toxici-ty. Advances in therapy, 29(2), 79–98. https://doi.org/10.1007/s12325-011-0100-7
Williams, C. M., Maher, C. G., Latimer, J., McLachlan, A. J., Hancock, M. J., Day, R. O., & Lin, C. W. (2014). Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial. Lancet (London, England), 384(9954), 1586–1596. https://doi.org/10.1016/S0140-6736(14)60805-9
Moore, R. A., Tramèr, M. R., Carroll, D., Wiffen, P. J., & McQuay, H. J. (1998). Quantitative systematic re-view of topically applied non-steroidal anti-inflammatory drugs. BMJ (Clinical research ed.), 316(7128), 333–338. https://doi.org/10.1136/bmj.316.7128.333
Mason, L., Moore, R. A., Edwards, J. E., Derry, S., & McQuay, H. J. (2004). Topical NSAIDs for acute pain: a meta-analysis. BMC family practice, 5, 10. https://doi.org/10.1186/1471-2296-5-10
Komatsu, T., & Sakurada, T. (2012). Comparison of the efficacy and skin permeability of topical NSAID prepa-rations used in Europe. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 47(5), 890–895. https://doi.org/10.1016/j.ejps.2012.08.016
Ballerini, R., Casini, A., Chinol, M., Mannucci, C., Giaccai, L., & Salvi, M. (1986). Study on the absorption of ketoprofen topically administered in man: comparison between tissue and plasma levels. International journal of clinical pharmacology research, 6(1), 69–72.
Wilbrink, B., Van der Veen, M. J., Huber, J., Van Roy, J. L., & Huber-Bruning, O. (1991). In vitro influence of ketoprofen on the proteoglycan metabolism of human normal and osteoarthritis cartilage. Agents and actions, 32(3‒4), 154–159. https://doi.org/10.1007/BF01980867
Weinberg, B. A., & Bealer, B. K. (2004). The World of Caffeine: The Science and Culture of the World's Most Popular Drug. Routledge, 235.
Derry, C. J., Derry, S., & Moore, R. A. (2012). Caffeine as an analgesic adjuvant for acute pain in adults. The Cochrane database of systematic reviews, (3), CD009281. https://doi.org/10.1002/14651858.CD009281.pub2
Syrova, H. O. (2010). Patent Ukrainy na korysnu model No.51082 "Sposib potentsiiuvannia protybolovoi dii kaliievoi soli 2,4-dykhlorbenzoinoi kysloty" [Patent of Ukraine for utility model No.51082 "Method of potentiation of the analgesic effect of the potassium salt of 2,h-dichlorobenzoic acid"], MPK: A61K 31/00 on June 25, 2010. Bull No.12.
Syrova, H. O., Hrabovetska, Ye. R., Shapoval, L. R., Nakonechna, S. A., Vakulenko, N. V., & Boiko, S. P. Patent Ukrainy na korysnu model No.59396. "Zastosuvannia kompozytsii nesteroidnykh protyzapalnykh zasobiv z kofeinom yak preparativ z antyeksudatyvnoiu aktyvnistiu" [Patent of Ukraine for utility model No.59396 "The use of composites of nonsteroidal anti-inflammatory drugs with caffeine as drugs with antiexudative activity"], MPK: A61KZ1/00-31/80 on May 10, 2011. Bull No.1.
Syrova, H. O., Bachynskyi, R. O., Vakulenko, N. V., & Boiko, Ye. P. (2011). Eksperymentalne vyvchennia vplyvu kofeinu na protybolovu diiu vidomykh nesteroidnykh protyzapalnykh zasobiv riznoi khimichnoi budovy [Ex-perimental study of the effect of caffeine on the anti-inflammatory effect of known non-steroidal anti-inflammatory drugs of different chemical structure]. Zaporozhskyi medytsynskyi zhurnal [Zaporizhzhya Medical Journal], 13(5), 60‒62.
Syrova, H. O. (2012). Eksperymentalne vyvchennia spetsyfichnoi dii kaliievoi soli 2,4-dykhlorbenzoinoi kysloty i yii kompozytsii z kofeinom [Experimental study of the specific action of the potassium salt of 2,h-dichlorobenzoic acid and other compositions with caffeine]. Ukrainskyi biofarmatsevtychnyi zhurnal [Ukrainian bio-pharmaceutical journal], 5/6, 59‒62.
Syrovaya, A. O., Bachinskiy, R. O., & Grabovetskaya, E. R. (2014). Creation of new drug compositions and pharmacological substantiation of their suitability for pain syndromes and inflammations in experimental rats. Inter Colleqas, 1, 13‒24.
Syrova, H. O. (2014). Eksperymentalne vyvchennia protybolovoi dii karbamazepinu, paratsetamolu i kofeinu ta yikh kompozytsii [Experimental study of the analgesic effect of carbamazepine, paracetamol and caffeine and their com-positions]. Ukrainskyi biofarmatsevtychnyi zhurnal [Ukrainian biopharmaceutical journal], 6, 8‒12.
Lukiyanova, L. V. (2016). Experiments on new pharmacological compositions under formalin edema. Der Pharma Chemica, 8(19), 182‒186.
Syrova, G. O., Lukianova, L. V., & Chalenko, N. M. (2018). The experimental research on the antiinflammato-ry action of the new piroxicamcaffeine pharmaceutical composition. Science Review, 4, (3(10)), 72‒76.
Syrova, G. O., Tishakova, T. S., Levashova, O. L., Savelieva, O. V. (2018). Biochemical Confirmation of An-ti-Inflammatory Activity of Oxicam Based Pharmaceutical Compositions. Jotcsa, 5(3), 1407‒1412.
Syrova, A., Lukyanova, L., Kozub, S., Zavada, О., Levashova, О., & Shaposhnik, V. (2020). Investigation of the Peripheral Analgesic Activity of Oxicams and Their Combinations with Caffeine. Turkish Journal оf Pharmaceuti-cal Sciences, 17(4), 408‒411.
Lukiyanova, L.V. (2016). Experiments on the influence of organic compounds with nitrogen and their composi-tions on the emotional-behavioral reactions of laboratory animals under formalin edema. Der Pharma Chemica, 8(19), 581‒585.
Syrova, G., Lukianova, L., Sinelnik, V., Krasnikova, Yu., Logina, S. (2019). Experimental investigation of the effect of pharmaceutical composition on the central nervous system. Inter Collegas, 6(3), 162‒167.
Karateev, A. E. (2017). What is safer for the gastrointestinal-tract: Coxibs or meloxicam? Modern Rheumatology Journal, 11(1), 72–78.
Malmstrom, K., Fricke, J. R., Kotey, P., Kress, B., & Morrison, B. (2002). A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model. Clinical therapeutics, 24(10), 1549–1560. https://doi.org/10.1016/s0149-2918(02)80059-5
Sommer, I. E., de Witte, L., Begemann, M., & Kahn, R. S. (2012). Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. The Journal of clinical psychiatry, 73(4), 414–419. https://doi.org/10.4088/JCP.10r06823
Arber, N., Eagle, C. J., Spicak, J., Rácz, I., Dite, P., Hajer, J., … & PreSAP Trial Investigators (2006). Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 355(9), 885–895. https://doi.org/10.1056/NEJMoa061652
Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., … & APC Study Investigators (2006). Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medi-cine, 355(9), 873–884. https://doi.org/10.1056/NEJMoa061355
Rahme, E., Barkun, A. N., Toubouti, Y., & Bardou, M. (2003). The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology, 125(2), 404–412. https://doi.org/10.1016/s0016-5085(03)00880-1
Basler, J. W., & Piazza, G. A. (2004). Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective in-hibitors for prostate cancer chemoprevention. The Journal of urology, 171(2 Pt 2), S59–S63. https://doi.org/10.1097/01.ju.0000107839.06670.27
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., … & Geis, G. S. (2000). Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheuma-toid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 284(10), 1247–1255. https://doi.org/10.1001/jama.284.10.1247
McGettigan, P., & Henry, D. (2013). Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS medicine, 10(2), e1001388. https://doi.org/10.1371/journal.pmed.1001388
Chalenko, N., Demchenko, A., & Syrova, G. (2019). Synthesis of potential antiexudative preparations for 2-((4-amino-5-(furan-2-il)-1,2,4-triazole-(4H)-3-yl)-sulfanyl)-N-acetamide series. Scientific Journal «ScienceRise: Pharmaceu-tical Science», 3(19), 22‒29.
Syrovaya, A. O., Chalenko, N. N., & Demchenko, A. M. (2016). The Synthesis of Potential Anti-Inflammatory Substances among 4-Amino-5-(Pyridin-4-yl)-1,2,4-Triazole(4H)-3-yl-Thioacetamides and their Chemical Modification. Der Pharma Chemica, 8(21), 17‒21.
Adamu, I., & Chalenko, N. (2017). Synthesis, prediction and experimental confirmation of pharmakological ac-tivity of 2-((4-amino-5-(furan-2-yl)-4H-1,2,4-triazole-3-yl)sulfanyl)-n-acetamide derivatives. X-th International Scientific Interdisciplinary Conference (ISIC) for medical students and young scientists, Ukraine, Kharkiv, 3.
Öztürk, S., Akkurt, M., Cansiz A., et al. (2004). 4-(4-Chlorophenyl)-3-(furan-2-yl)-1H-1,2,4-triazole-5(4H)-thione. Acta Cryst, 60, 425‒427.
Ali, A., Nasim, V., Abbas, T. S., Abbas, K. S. (2007). Synthesis, anticonvulsant and muscle relaxant activities of substituted 1,3,4-oxadiazole, 1,3,4-thiadiazole and 1,2,4-triazole. Acta chim (Sloven.), 2(54), 317‒324.
Cai, H., Huang, X., Xu, S., Shen, H., Zhang, P., Huang, Y., … & Xu, J. (2016). Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy. European journal of medicinal chemistry, 108, 89–103. https://doi.org/10.1016/j.ejmech.2015.11.013
Sondhi, S.M., Dinodia, M., & Singh, J. (2007). Heterocyclic Compounds as Anti-Inflammatory Agents. Cur-rent Bioactive Compounds, 2(3), 91‒108.
Jiang, B., Zeng, Y., Li, M. J., Xu, J. Y., Zhang, Y. N., Wang, Q. J., … & Wu, X. M. (2010). Design, syn-thesis, and biological evaluation of 1,5-diaryl-1,2,4-triazole derivatives as selective cyclooxygenase-2 inhibitors. Archiv der Pharmazie, 343(9), 500–508. https://doi.org/10.1002/ardp.200900227
Cao, L., Zhang, L., & Cui, P. (2004). Synthesis of 3-(3-alkyl-5-thioxo-1H-4,5-dihydro-1,2,4-triazol-4-yl)aminocarbonylchromones. Chem. Heterocyclic Compounds, 40(5), 635–640.
Singh, R., Sylvain, C., & Holland, S. (2013). Pat. US 8389557 B2, A61K31/41 "Triazole derivatives useful as Axl inhibitors".
Plech, T., Wujec, M., & Majewska, M. (2013). Microbiologically active Mannich bases derived from 1,2,4-triazoles. The effect of C-5 substituent on antibacterial activity. Med. Chem. Res., 22, 2531‒2537.
"Inter Collegas" is an open access journal: all articles are published in open access without an embargo period, under the terms of the CC BY-NC-SA (Creative Commons Attribution ‒ Noncommercial ‒ Share Alike) license; the content is available to all readers without registration from the moment of its publication. Electronic copies of the archive of journals are placed in the repositories of the KhNMU and V.I. Vernadsky National Library of Ukraine.
Copyright Agreement
1. This Agreement on the transfer of rights to use the work from the Co-authors to the publisher (hereinafter the Agreement) is concluded between all the Co-authors of the work, represented by the Corresponding Author, and Kharkiv National Medical University (hereinafter the University), represented by an authorized representative of the Editorial Board of scientific journals (hereinafter the Editorial Board).
2. This Agreement is an accession agreement within the meaning of clause 1 of Article 634 of the Civil Code of Ukraine: that is, a contract, "the terms of which are established by one of the parties in forms or other standard forms, which can be concluded only by joining the other party to the proposed contract as a whole. The other party cannot offer its terms of the contract." The party that established the terms of this contract is the University.
3. If there is more than one author, the authors choose the Corresponding Author, who communicates with the Editorial Board on his own behalf and on behalf of all Co-authors regarding the publication of a written work of a scientific nature (article or review, hereinafter referred to as the Work).
4. The contract begins from the moment of submission of the manuscript of the Work by the Corresponding Author to the Editorial Board, which confirms the following:
4.1. all Co-authors of the Work are familiar with and agree with its content, at all stages of reviewing and editing the manuscript and the existence of the published Work;
4.2. all Co-authors of the Work are familiar with and agree to the terms of this Agreement.
5. The published Work is in electronic form in public access on the websites of the University and any websites and electronic databases in which the Work is posted by the University and is available to readers under the terms of the "Creative Commons" license (Attribution NonCommercial Sharealike 4.0 International)" or more free licenses "Creative Commons 4.0".
6. The Corresponding Author transfers, and the University receives, the non-exclusive property right to use the Work by placing the latter on the University's websites for the entire term of copyright. The University participates in the creation of the final version of the Work by reviewing and editing the manuscript of the article or review provided to the Editorial Board by the Corresponding Author, translating the Work into any languages. For the participation of the University in the finalization of the Work, the Co-authors agree to pay the invoice issued to them by the University, if such payment is provided by the University. The size and procedure of such payment are not the subject of this contract.
7. The University has the right to reproduce the Work or its parts in electronic and printed forms, to make copies, permanent archival storage of the Work, distribution of the Work on the Internet, repositories, scientometric databases, commercial networks, including for monetary compensation from third parties.
8. The co-authors guarantee that the manuscript of the Work does not use works whose copyright belongs to third parties.
9. The authors of the Work guarantee that at the time of submission of the manuscript of the Work to the Editorial Board, the property rights to the Work belong only to them, neither in whole nor in part have they been transferred to anyone (not alienated), they are not the subject of a lien, litigation or claims by third parties.
10. The Work may not be posted on the University's website if it violates a person's right to the privacy of his personal and family life, harms public order and health.
11. The work may be withdrawn by the Editorial Board from the University websites, libraries and electronic databases where it was placed by the Editorial Board, in cases of detection of violations of the ethics of the authors and researchers, without any compensation for the losses of the Co-authors. At the time of submission of the manuscript to the Editorial Board and all stages of its editing and review, the manuscript must not have already been published or submitted to other editorial offices.
12. The right transferred under this Agreement extends to the territory of Ukraine and foreign countries.
13. The rights of Co-authors include the requirement to indicate their names on all copies of the Work or during any public use or public mention of the Work; the requirement to preserve the integrity of the Work; legal opposition to any distortion or other encroachment on the Work, which may harm the honor and reputation of the Co-authors.
14. Co-authors have the right to control their personal non-property rights by familiarizing themselves with the text (content) and form of the Work before its publication on the University's website, when transferring it to a printing company for reproduction or when using the Work in other ways.
15. The Co-authors, in addition to the property rights not transferred under this Agreement and taking into account the non-exclusive nature of the rights transferred under this Agreement, retain the property rights to finalize the Work and to use certain parts of the Work in other works created by the Co-authors.
16. The Co-authors are obliged to notify the Editorial Board of all errors in the Work, discovered by them independently after the publication of the Work, and to take all measures to eliminate such errors as soon as possible.
17. The University undertakes to indicate the names of the Co-authors on all copies of the Work during any public use of the Work. The list of Co-authors may be shortened according to the rules for the formation of bibliographic descriptions determined by the University or third parties.
18. The University undertakes not to violate the integrity of the Work, to agree with the Corresponding Author on all changes made to the Work during processing and editing.
19. In case of violation of their obligations under this Agreement, its parties bear the responsibility defined by this Agreement and the current legislation of Ukraine. All disputes under the Agreement are resolved through negotiations, and if the negotiations do not resolve the dispute – in the courts of the city of Kharkiv.
20. The parties are not responsible for the violation of their obligations under this Agreement, if it occurred through no fault of theirs. The party is considered innocent if it proves that it has taken all measures dependent on it for the proper fulfillment of the obligation.
21. The Co-authors are responsible for the truthfulness of the facts, quotes, references to legislative and regulatory acts, other official documentation, the scientific validity of the Work, all types of responsibility to third parties who have claimed their rights to the Work. The co-authors reimburse the University for all costs caused by claims of third parties for infringement of copyright and other rights to the Work, as well as additional material costs related to the elimination of identified defects.